The Rs 30.24 crore IPO, which comprised entirely a fresh issue of 14.54 lakh shares, witnessed overwhelming investor interest during the three-day bidding period. The issue was subscribed 385.32 times, driven by robust participation across all investor categories.
The non-institutional investor (NII) segment led the demand with a subscription of 597.23 times, while the retail portion was subscribed 401.36 times. The qualified institutional buyer (QIB) category attracted bids for 196.77 times the shares reserved.
The company had fixed the IPO price at Rs 208 per share. Retail investors were required to apply for a minimum of 1,200 shares, translating into an investment of Rs 2.50 lakh.
Incorporated in 2024, Avience Biomedicals manufactures, supplies and exports molecular diagnostic solutions catering to the biotechnology, genomics and in-vitro diagnostics (IVD) industry. Its portfolio includes rapid test kits, molecular diagnostic products, biochemistry and hematology analysers, reagents and medical devices. The company serves pathology laboratories, hospitals, research centres and government institutions across India and overseas, while also trading in medical equipment.
The IPO proceeds will be used to partly fund the setting up of a new manufacturing facility at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Uttar Pradesh, meet working capital requirements and for general corporate purposes.
On the financial front, the company reported total income of Rs 45.97 crore and a net profit of Rs 7.23 crore for FY25. For the nine months ended January 2026, it posted revenue of Rs 41.94 crore and a profit after tax of Rs 5.74 crore.While the grey market premium suggests strong investor optimism ahead of listing, GMP is an unofficial indicator and does not guarantee listing gains.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
